Hello.
This is Daily Stock, delivering in-depth analysis of key supply-demand flows and liquidity shifts in the KOSDAQ market.
[Image: /stdaily/uploads/202606/gen_6a23d3eeac1955.03167545.png]
Key Summary
While the KOSPI has recently staged a historic rally, breaking through the 8,000-point mark, the KOSDAQ has experienced severe decoupling, barely holding onto the 1,000-point threshold (currently at 1,002.44).
Amidst a heavy concentration of capital in large-cap semiconductor stocks, the supply-demand void in KOSDAQ is worsening, as evidenced by a decline in outstanding margin debt balances.
Nevertheless, backed by consecutive global technology export achievements from K-biotech firms, bargain-hunting inflows are being detected in KOSDAQ healthcare and active ETFs.
Expectations for the execution of policy funds such as the National Growth Fund in the second half of the year are emerging as a pivotal variable that could improve supply-demand dynamics for KOSDAQ's bio sector.
Market Overview
[Image: /stdaily/uploads/202606/gen_6a23d3fb5829e0.73358956.png]
As of the close on June 6, 2026, the KOSDAQ index stands at 1,002.44, locked in a fierce battle to defend the crucial 1,000-point support line.
In stark contrast, the KOSPI index is soaring at 8,160.59, highlighting the extreme concentration of capital within the domestic equity markets.
The Nasdaq index, a global financial benchmark, is trading at 25,709.43 points, while the USD/KRW exchange rate continues its strong trend at 1,559.00 KRW.
According to Daily Stock's proprietary Fear & Greed Index, the KOSPI index currently rests in the "Neutral" zone (51.8), compared to "Neutral" (57.5) a week ago, "Greed" (66.5) a month ago, and "Fear" (32.9) three months ago.
The Nasdaq Fear & Greed Index is also in the "Neutral" territory (42.1), compared to "Neutral" (59.5) a week ago, "Greed" (67.3) a month ago, and "Neutral" (58.0) three months ago.
Financial Analysis
The KOSDAQ healthcare sector is striving to improve its qualitative fundamentals based on the scale of license-out deals, which represent tangible pipeline milestones.
Notably, the first KOSDAQ active ETFs in Korea—"KoAct KOSDAQ Active" and "TIME KOSDAQ Active"—garnered significant attention by attracting over 1 trillion KRW in cumulative assets soon after their listings.
According to recent tallies, the net asset value (AUM) of KoAct KOSDAQ Active stands at approximately 628.9 billion KRW (as of June 1).
Mirae Asset Global Investments' recently launched "TIGER Tech Transfer Bio Active" has seen steady inflows since listing, growing to an AUM of approximately 151 billion KRW (based on the latest disclosures).
This ETF strategically concentrates its portfolio on biotechs with proven global licensing track records, such as LigaChem Biosciences, OliX Pharmaceuticals, and ABL Bio.
| ETF Name | Ticker | Core Holdings / Key Characteristics | Total Expense Ratio (Annual) | Net Asset Value (Latest) |
|---|---|---|---|---|
| TIGER Tech Transfer Bio Active | 0168K0 | Selective investment in proven tech exporters and high-potential biotechs | 0.55% | Approx. 151.0 billion KRW |
| KoAct KOSDAQ Active | 0163Y0 | High-growth KOSDAQ leaders in bio, semiconductor equipment, materials, etc. | 0.50% | Approx. 628.9 billion KRW |
| TIME KOSDAQ Active | 0162Y0 | Core large-cap allocation combined with theme-rotation strategies | 0.80% | Approx. 493.8 billion KRW |
| KODEX Bio | 244580 | Equal-weighted passive investment in listed domestic biotech firms | 0.45% | Approx. 255.3 billion KRW |
Valuation
As the KOSDAQ index hovers just above the 1,000 level, valuation multiples across the KOSDAQ healthcare sector are reaching highly attractive levels.
Due to the recent market correction, Price-to-Sales (PSR) burdens for several biotech stocks—which had previously climbed on excessive expectations—have eased substantially.
Passive ETFs that mechanically track the index had no choice but to absorb the full impact of the broader market decline.
In contrast, active ETFs utilize fundamental analysis to weed out distressed companies and identify high-quality players with actual revenue or licensing momentum, thereby establishing a valuation floor.
With uncertainty regarding the path of US interest rate cuts persisting, concentrated portfolios focusing on biotechs with verified technical capabilities could serve as the key to mid-to-long-term valuation re-rating.
Expert & Institutional Analysis
[Image: /stdaily/uploads/202606/gen_6a23d406280307.74036382.png]
Market experts point out that the short-term capital rush into semiconductors and large-cap stocks has left a liquidity vacuum for small and mid-cap growth stocks on the KOSDAQ.
Jaehong Yoon, an analyst at Mirae Asset Securities, projected: "Through the National Growth Fund, which will be raised to a scale of 150 trillion KRW over five years, approximately 10.4 trillion KRW in capital could flow into the KOSDAQ market via direct and indirect channels."
He viewed the diversification of market participants positively, noting that institutional and foreign investors are expanding their presence in KOSDAQ, which was historically dominated by retail traders.
Furthermore, asset management industry insiders emphasize that because healthcare represents a massive portion of the KOSDAQ 150 index, a normalization of healthcare inflows is essential for any meaningful rebound of the KOSDAQ index.
Under this scenario, large-cap biotechs and active ETFs, which are highly accessible to institutional and foreign investors, could act as primary funnels for incoming capital.
Risk Factors
Concerns over prolonged high global interest rates and a strong dollar environment hovering above 1,500 KRW (currently USD/KRW is at 1,559.00) pose burdens for the KOSDAQ healthcare market, which is heavily weighted toward growth stocks.
Retail investor sentiment has cooled, with the KOSDAQ margin debt balance recently hitting a yearly low of approximately 9.8351 trillion KRW.
Sudden negative events at individual firms, such as clinical trial failures or the return of out-licensed pipelines, can trigger synchronized downturns across the entire sector.
Additionally, because small and mid-cap KOSDAQ stocks have lower liquidity than large caps, there is an inherent gap-volatility risk where stock price swings can amplify during ETF rebalancing or abrupt capital outflows.
Investment Outlook
The KOSDAQ market is currently navigating a period of short-term volatility, driven by a severe performance gap with the KOSPI and capital outflows.
However, analysts point out that the structural growth story of K-bio—supported by domestic policy momentum and an increasing volume of global technology transfers—remains intact.
Therefore, for investors seeking to benefit from a potential recovery in KOSDAQ healthcare while avoiding the high volatility of individual stocks, utilizing well-diversified active ETFs presents a rational alternative.
Rather than chasing short-term spikes, a staggered accumulation strategy while monitoring second-half policy fund executions and regulatory improvements appears highly viable.
Investor Checklist Q&A
Q1. What is the primary cause behind the KOSDAQ index falling toward the 1,002 level?
A1. Major concentrations of capital in large-cap KOSPI semiconductor stocks and single-stock leveraged ETFs have drained liquidity from KOSDAQ small and mid-cap growth stocks, leading to a drop in outstanding margin debt.
Q2. What is the biggest difference between KOSDAQ active ETFs and standard passive ETFs?
A2. While passive ETFs mechanically replicate a specific benchmark index, active ETFs allow fund managers to select promising stocks and dynamically adjust holdings to target excess returns (alpha) over the benchmark index.
Q3. Why is the "License-out (Technology Transfer)" theme receiving so much attention in healthcare ETFs?
A3. As global big pharma companies face patent expiries, their demand to source external technology is rising. This highlights the intrinsic value of domestic biotech firms that have proven or high-potential technology licensing portfolios.
Q4. How will the National Growth Fund affect KOSDAQ healthcare supply-demand?
A4. An estimated 10.4 trillion KRW is expected to flow into the KOSDAQ market, attracting institutional and foreign buyers. This creates a highly favorable backdrop for the healthcare sector, which commands a massive portion of KOSDAQ's total market capitalization.
Q5. Is the USD/KRW exchange rate in the mid-1,500s (1,559.00 KRW) favorable for biotech companies?
A5. For biotech firms that secure dollar-denominated technology licensing deals with global pharmaceutical giants, a strong dollar translates directly into foreign exchange gains, boosting KRW-denominated revenues and overall profitability.